Cost-utility analysis of rezivertinib versus gefitinib as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer
- VernacularTitle:瑞齐替尼对比吉非替尼一线治疗EGFR突变阳性晚期非小细胞肺癌的成本-效用分析
- Author:
Xiaowei ZHU
1
;
Tongming ZHU
1
;
Jia YI
1
;
Wenqiang LI
1
;
Piaopiao LU
1
;
Aizong SHEN
1
Author Information
1. School of Pharmacy，Anhui University of Chinese Medicine，Hefei 230012，China;Anhui Provincial Drug Clinical Comprehensive Evaluation Technology Center，Hefei 230001，China;Key Laboratory of Public Health Social Governance，Philosophy & Social Sciences of Anhui Province，Hefei 230032，China;Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations & Clinical Pharmacy，Hefei 230001，China
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
EGFR mutation;
rezivertinib;
gefitinib;
cost-effectiveness analysis;
Markov model
- From:
China Pharmacy
2026;37(1):55-60
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of rezivertinib versus gefitinib as first-line treatment for epidermal growth factor receptor （EGFR） mutation-positive advanced non-small cell lung cancer （NSCLC） from the perspective of the Chinese healthcare system. METHODS A Markov model was constructed based on the REZOR trial data， with a cycle length of 3 weeks and a study duration of 5 years. Both costs and health outcomes were discounted at an annual rate of 5%. A cost-utility analysis was conducted using 3 times China’s 2024 per capita gross domestic product as the willingness-to-pay （WTP） threshold. The economic differences between the rezivertinib regimen versus the gefitinib regimen were evaluated using the incremental cost- effectiveness ratio （ICER） and incremental net monetary benefit （INMB）. Sensitivity and scenario analyses were performed to verify the robustness of the model. RESULTS Compared to the gefitinib regimen， the rezivertinib regimen saved 225 310.47 yuan and gained an additional 0.57 quality- adjusted life years （QALYs）， resulting in an ICER of －395 562.80 yuan/QALY， which was much lower than the WTP threshold of this study， indicating that rezivertinib had an absolute economic advantage. The INMB analysis （389 041.26 yuan） further validated this conclusion. One-way and probabilistic sensitivity analyses confirmed the robustness of the model. Scenario analysis， incorporating a 15% reduction in drug prices and adjustments to the utility values for progression free survival and progression disease， yielded consistent results with the base case analysis. CONCLUSIONS Compared to gefitinib， rezivertinib as a first-line treatment for EGFR mutation-positive advanced NSCLC has an absolute economic advantage.
